Getting to Know Pfizer’s New Chief Medical Officer Aida Habtezion
The Facts About Pfizer and BioNTech’s COVID-19 Vaccine
COVID-19 SCIENTIFIC RESOURCES
In His Shoes (or Hiking Boots)
VISIT OUR COVID-19 HUB
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who are at risk for pregnancy.